Inhibikase Therapeutics, Inc.
IKT • NASDAQ
Inhibikase Therapeutics, Inc. is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Mark T. Iwicki, with a market cap of $221.8M.
CEOMark T. Iwicki
Next Earnings
No upcoming earnings scheduled for Inhibikase Therapeutics, Inc.
No earnings announcement scheduled
Earnings History
Past 12 earnings reports for Inhibikase Therapeutics, Inc.
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 26, 2026 | Q1 2026 | -$0.10Est: -$0.12 | +16.7% | - | — | — |
| Nov 14, 2025 | Q3 2025 | -$0.13Est: -$0.12 | -8.3% | - | — |  10-Q |
| Aug 14, 2025 | Q2 2025 | -$0.11Est: -$0.09 | -22.2% | - | — | 10-Q |
| May 14, 2025 | Q1 2025 | -$0.15Est: -$0.11 | -36.4% | - | — | 10-Q |
| Nov 14, 2024 | Q3 2024 | -$0.65Est: -$0.67 | +3.0% | - | — | 10-Q |
| Aug 14, 2024 | Q2 2024 | -$0.66Est: -$0.67 | +1.5% | - | — | 10-Q |
| May 15, 2024 | Q1 2024 | -$0.73Est: -$0.79 | +7.6% | - | — | 10-Q |
| Mar 27, 2024 | Q4 2023 | -$0.64Est: -$0.85 | +24.7% | $1.0K | — | 10-K |
| Nov 14, 2023 | Q3 2023 | -$0.86Est: -$1.19 | +27.7% | $79.6K | — | — |
| Aug 14, 2023 | Q2 2023 | -$1.11Est: -$0.92 | -20.7% | $116.4K | — | — |
| May 15, 2023 | Q1 2023 | -$0.96Est: -$0.84 | -14.3% | $64.5K | — | — |
| Mar 31, 2023 | Q4 2022 | -$1.02Est: -$1.14 | +10.5% | $63.6K | — | — |